Ausun Pharm(SH:603229) Xin Lang Cai Jing·2026-01-19 01:39Group 1 - The core viewpoint of the news is that Aoxiang Pharmaceutical experienced a slight decline in stock price and has notable financing activities, indicating a mixed sentiment among investors [1] - On January 16, Aoxiang Pharmaceutical's stock fell by 0.79%, with a trading volume of 75.74 million yuan. The net financing purchase for the day was 574,400 yuan, with a total financing and securities balance of 392 million yuan [1] - The financing balance of Aoxiang Pharmaceutical accounts for 4.72% of its market capitalization, which is above the 70th percentile of the past year, indicating a relatively high level of financing [1] Group 2 - Aoxiang Pharmaceutical, established on April 22, 2010, specializes in the research, production, and sales of specialty APIs and intermediates, with a revenue composition that includes liver disease (31.29%), cardiovascular (18.94%), and antibacterial (18.56%) products [2] - For the period from January to September 2025, Aoxiang Pharmaceutical reported a revenue of 646 million yuan, a year-on-year decrease of 6.40%, and a net profit attributable to shareholders of 207 million yuan, down 9.59% year-on-year [2] - As of September 30, 2025, Aoxiang Pharmaceutical had 32,000 shareholders, an increase of 5.64% from the previous period, with an average of 25,948 circulating shares per person, a decrease of 5.34% [2] Group 3 - Aoxiang Pharmaceutical has distributed a total of 286 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder of Aoxiang Pharmaceutical, holding 5.36 million shares, an increase of 160,600 shares from the previous period [3]